These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23286855)

  • 1. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance.
    Zoulim F; Locarnini S
    Liver Int; 2013 Feb; 33 Suppl 1():116-24. PubMed ID: 23286855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of treatment failure in chronic hepatitis B.
    Zoulim F; Locarnini S
    J Hepatol; 2012; 56 Suppl 1():S112-22. PubMed ID: 22300461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic hepatitis B: preventing, detecting, and managing viral resistance.
    Keeffe EB; Dieterich DT; Pawlotsky JM; Benhamou Y
    Clin Gastroenterol Hepatol; 2008 Mar; 6(3):268-74. PubMed ID: 18328434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of antiviral drug resistance in chronic hepatitis B.
    Bang KB; Kim HJ
    World J Gastroenterol; 2014 Sep; 20(33):11641-9. PubMed ID: 25206270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy versus combination therapy for the treatment of chronic hepatitis B.
    Carey I; Harrison PM
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1655-66. PubMed ID: 19852566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathobiology of HBV mutants and clinical impact for treatment monitoring.
    Si Ahmed SN; Zoulim F
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):309-20. PubMed ID: 19344244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and management of drug resistance for antihepatitis B treatment.
    Yuen MF; Fung J; Wong DK; Lai CL
    Lancet Infect Dis; 2009 Apr; 9(4):256-64. PubMed ID: 19324298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hepatitis B patients with antiviral resistance.
    Fung SK; Lok AS
    Antivir Ther; 2004 Dec; 9(6):1013-26. PubMed ID: 15651760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management and prevention of drug resistance in chronic hepatitis B.
    Zoulim F; Durantel D; Deny P
    Liver Int; 2009 Jan; 29 Suppl 1():108-15. PubMed ID: 19207973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of antiviral resistance in patients with chronic hepatitis B.
    Locarnini S; Hatzakis A; Heathcote J; Keeffe EB; Liang TJ; Mutimer D; Pawlotsky JM; Zoulim F
    Antivir Ther; 2004 Oct; 9(5):679-93. PubMed ID: 15535405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue.
    Ma H; Jia J
    Liver Int; 2013 Feb; 33 Suppl 1():133-6. PubMed ID: 23286857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to overcome antiviral-resistant hepatitis B virus?
    Song BC
    Intervirology; 2010; 53(1):29-38. PubMed ID: 20068338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
    Locarnini S; Warner N
    Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
    Dusheiko G
    Liver Int; 2013 Feb; 33 Suppl 1():137-50. PubMed ID: 23286858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral therapy of chronic hepatitis B.
    Zoulim F
    Antiviral Res; 2006 Sep; 71(2-3):206-15. PubMed ID: 16716414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral therapy of chronic hepatitis B: prevention of drug resistance.
    Fournier C; Zoulim F
    Clin Liver Dis; 2007 Nov; 11(4):869-92, ix. PubMed ID: 17981233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.
    Cheng PN; Chang TT
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):569-79. PubMed ID: 18847396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H; Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Kobayashi M; Kumada H
    J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
    Yap DY; Tang CS; Yung S; Choy BY; Yuen MF; Chan TM
    Transplantation; 2010 Aug; 90(3):325-30. PubMed ID: 20562676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.